← Oncology Approval Tracker

FDA DECISION ·

Opdivo

nivolumab · Bristol Myers Squibb

FDA approvalNew or expanded indicationMelanoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

The adjuvant indication after complete resection of melanoma with nodal involvement or metastatic disease expanded to patients aged 12 or older.

LAMPGEN ANALYSIS

Why it matters

The pediatric supplement extended a postsurgical use distinct from active unresectable disease.

What research teams should watch

Document nodal or metastatic involvement and complete resection. The subsequent stage IIB and IIC indication was a separate action.

PRIMARY RECORDS

Sources